Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Oct 23;4(12):1675–1692. doi: 10.1038/s43018-023-00656-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 5 — (a) Schematic summarizing RN2 cell engraftment, antibody treatment schedule, and disease burden assessment. (b) Impact of control or IgG2A anti-U5 snRNP200 antibody treatment on CD19 (left) and CD11b (right) cells in the peripheral blood. Bar graphs represent mean ± SEM shown. Control group n = 9 mice; treated group n = 10 mice. (p value from paired t-test; **p = 0.032. (c) Representative FACS plots of data from (b). (d) Gating schema for identification, quantification, and FcR expression characterization of immune cell subsets in CD45.1 mice engrafted with CD45.2 AML cells. From the live, CD45.2⁻ gate: NK cells = CD11b⁻NK1.1⁺, DCs = NK1.1⁻CD11C⁺, Monocyte/Macrophage = NK1.1⁻CD11c⁻CD11b⁺Ly6g⁻; Neutrophils (PMN) = NK1.1⁻CD11c⁻CD11b⁺Ly6g⁺.

Source data